Oruka director granted 9,136 stock options
BALL KRISTINE M reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BALL KRISTINE M reported acquisition or exercise transactions in this Form 4 filing.
Oruka Therapeutics director Kristine M. Ball received a grant of stock options covering 9,136 shares of common stock at 55.23 per share. The options vest in 12 equal monthly installments beginning on June 2, 2026 and expire on June 1, 2036. Following this award, she holds options for 9,136 shares directly.
Insider Trade Summary
Grant/Award: 9,136 shares
Grant/Award
1 txn
Insider
BALL KRISTINE M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 9,136 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 9,136 contracts (Direct)
Footnotes (1)
- F1. The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.
Key Figures
Options Granted: 9,136 options
Exercise Price: 55.23 per share
Underlying Shares: 9,136 shares
+3 more
6 metrics
Options Granted
9,136 options
Stock Option (right to buy) grant to director on June 2, 2026
Exercise Price
55.23 per share
Conversion or exercise price of stock option grant
Underlying Shares
9,136 shares
Common Stock underlying the stock option award
Post-grant Option Holdings
9,136 options
Total derivative shares following transaction, held directly
Vesting Schedule
1/12 monthly
From June 2, 2026, one-twelfth of options vest each month
Expiration Date
June 1, 2036
Expiration of the granted stock options
Key Terms
Stock Option (right to buy), grant/award acquisition, vesting, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
vesting financial
"The option vests as to 1/12 of the underlying shares monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-01T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative financial
"transaction_type: "derivative""
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Oruka Therapeutics (ORKA) disclose in this Form 4?
Oruka Therapeutics reported a stock option grant to director Kristine M. Ball for 9,136 shares of common stock. The award is a compensation-related grant, not an open-market purchase or sale, and reflects standard equity-based director compensation.
How many Oruka Therapeutics (ORKA) options were granted to Kristine M. Ball?
Kristine M. Ball was granted stock options on 9,136 underlying shares of Oruka Therapeutics common stock. This award increases her derivative holdings to options on 9,136 shares, according to the post-transaction ownership figure in the Form 4 filing.
What is the exercise price of Kristine M. Ball’s ORKA stock options?
The stock options granted to Kristine M. Ball carry an exercise price of 55.23 per share. This price is the amount she would need to pay for each share of Oruka Therapeutics common stock upon exercising the options in the future.
When do Kristine M. Ball’s Oruka Therapeutics (ORKA) options vest?
The options vest as to one-twelfth of the underlying shares each month starting June 2, 2026. This means the 9,136 options vest in 12 equal monthly installments, gradually becoming exercisable over the one-year period following that date.
When do the granted Oruka Therapeutics (ORKA) stock options expire?
Kristine M. Ball’s stock options expire on June 1, 2036. After this expiration date, any unexercised options will lapse, and she will no longer have the right to purchase Oruka Therapeutics common shares under this particular grant.
Is this Oruka Therapeutics (ORKA) Form 4 a buy or a sell transaction?
This Form 4 reflects an acquisition of stock options as a grant or award, not an open-market buy or sell. The transaction is coded as “A” for grant/award acquisition and represents compensation rather than a discretionary market trade.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates